8.90
+7.36%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alpha Cognition
From its filings with the US Securities and Exchange Commission
Alpha Cognition is based in Grapevine, Texas and is incorporated in British Columbia, Canada. Its shares trade on Nasdaq under the ticker ACOG. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $10.2m and a net loss of $20.7m. At that date it held total assets of $79.7m and shareholders' equity of $62.5m.
ZUNVEYL with Medicare payors, and developing strategic and clinical partnerships with consultant pharmacists and long-term care pharmacies.
Execute commercialization of the FDA-approved ZUNVEYL oral formulation. ZUNVEYL is the second oral therapy available for Alzheimer’s patients in the past decade. The Company may pursue new business opportunities for commercial and/or development partners both domestically and internationally.
Commercialization – The Company completed commercialization preparations for ZUNVEYL in the first quarter of 2025 and initiated commercial launch on March 19, 2025. Since launch, the Company has been executing its commercialization strategy, including targeting the LTC market, prioritizing LTC customers, communicating the product’s clinical positioning, and implementing marketing and operational plans designed to support adoption.
Commercial supply of ZUNVEYL was established in the first quarter of 2025, and wholesalers were stocked with the necessary dosage strengths of ZUNVEYL (5 mg, 10 mg, and 15 mg) to support launch and ongoing distribution.
FDA regulatory approval does not guarantee approval and/or distribution in other territories.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Sept 2018
- Employees
- 72
- Head office
- 1452 HUGHES RD., STE. 200, GRAPEVINE, TX, 76051
- Incorporated in
- A1
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Len MertzIndependent Chairman of the Board
- Mr. Michael McfaddenChief Executive Officer, Director, since 2021$542,686
- Mr. Henry DuInterim Chief Financial Officer, Vice President - Finance and Accounting
- Ms. Lauren D'AngeloChief Operating Officer$530,213
- Mr. Kenneth CawkellCorporate Secretary, Director, since 2021$97,230
- Mr. Rajeev BakshiIndependent Director
- Mr. John HavensIndependent Director
- Mr. Phillip MertzIndependent Director$30,000
- Dr. Robert WillsIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alpha Cognition's pipeline includes ALPHA-1062 for Alzheimer's disease with minimal side effects.
- ALPHA-0602 gene therapy targets progranulin for ALS treatment in preclinical stages.
- ALPHA-1062 is being developed as an intranasal formulation for traumatic brain injury.
Weaknesses
- The company has only four pipeline products including ALPHA-1062 and ALPHA-0602.
- Alpha Cognition's clinical stage development requires significant funding for ongoing trials.
- The company's focus on neurodegenerative diseases limits market diversification.
Opportunities
- Expanding ALPHA-1062 to treat moderate to severe Alzheimer's dementia with memantine combination.
- Developing ALPHA-0602 for ALS treatment as a gene therapy program.
- The growing market for neurodegenerative disease treatments in Canada.
Threats
- Competition from other biotech firms in the Alzheimer's disease market.
- Regulatory challenges for gene therapy programs like ALPHA-0602.
- Potential delays in clinical trials for ALPHA-1062 and ALPHA-0602.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.